HBIO Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

03
Precio $8.34
Capitalización Bursátil (MRQ) $38M
P/E (TTM) -5.6
BPA (TTM) $-1.50
Ingresos (TTM) $88M
ROE (TTM) -89.9%
Deuda/Capital (MRQ) 4.9
Rango 52S $0–$8

HBIO Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

04
rango
barras

La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.

Divisiones de acciones 2
Fecha ex-dividendo División Tipo
16 de marzo de 2026 1-for-10 Inversa
4 de noviembre de 2013 1319-for-1000 Adelante

Acerca de Harvard Bioscience, Inc. - Common Stock Descripción general de la empresa de Wikipedia

05 · wikidata

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

History

Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.

The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.

In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.

From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.

In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.

The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.

In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).

In 2015 the company acquired HEKA Electronik of Germany.

In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.

In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.

James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.

For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.

In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.

In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.

Products

Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.

Finance

The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.

In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

sectorHealthcare industriaLife Sciences Tools & Services empleados316 paísUS

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

06
Ingresos$87M
2016-12-31 → 2025-12-31
BPA$-1.28
2016-12-31 → 2025-12-31
Flujo de caja libre$5M
2018-12-31 → 2025-12-31
Margen neto-11.9%
2016-12-31 → 2025-12-31
Valoración y ratios 07–12

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica Tendencia a 5 años HBIO promedio 5A Mediana de Pares Veredicto
P/E (TTM) -5.6promedio 5A ≈-21.7 ≈-21.7 · ·
P/S (TTM) 0.4promedio 5A ≈1.4 ≈1.4 · ·
P/C (MRQ) 5.1promedio 5A ≈2.4 ≈2.4 · ·
EV / EBITDA -1.3promedio 5A ≈51.1 ≈51.1 · ·
Precio / FCF (TTM) -33.9promedio 5A ≈802.1 ≈802.1 · ·
Precio / Flujo de Caja (TTM) 58.3promedio 5A ≈83.3 ≈83.3 · ·
EV / Revenue (EV / Ingresos) 0.7promedio 5A ≈1.7 ≈1.7 · ·
EV / FCF 11.8promedio 5A ≈900.4 ≈900.4 · ·
Precio / Valor Contable Tangible (MRQ) 31.7 · · ·

La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.

valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

14
Sorpresa Media -18.3%
Próximo informe Nov 04, 2026
PeríodoInformeEPS ActualEPS est.Sorpresa
30 de junio de 2026 Ago 11, 2026 $-0.14 $-0.21 34.6%
31 de marzo de 2026 May 12, 2026 $-0.77 $-0.63 -21.8%
31 de diciembre de 2025 $0.00 $0.36 -100.0%
30 de septiembre de 2025 $0.00 $0.05 -100.0%
30 de junio de 2025 $-0.10 $-0.10 2.0%
31 de marzo de 2025 $-0.10 $-0.41 75.5%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

15
Estado de resultados 17
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue $87M$94M$112M$113M$119M$102M$116M$121M$77M$105M$109M$109M
Cost of Revenue $37M$39M$46M$53M$51M$44M$52M$58M$38M$56M$60M$59M
Gross Profit $50M$55M$66M$61M$68M$58M$64M$63M$39M$48M$49M$49M
R&D Expense $9M$10M$12M$12M$11M$9M$11M$11M$6M$5M$6M$5M
SG&A Expense $18M$21M$23M$24M$24M$24M$23M$21M$18M$21M$20M$17M
Operating Expenses $98M$61M$64M$68M$66M$58M$64M$62M$40M$51M$50M$43M
Operating Income $-49M$-6M$2M$-7M$2M$221.0K$377.0K$984.0K$-635.0K$-3M$-2M$7M
Interest Expense ·······$5M$713.0K$639.0K$846.0K$990.0K
Other Non-op $-3M$-325.0K$-227.0K$302.0K$-666.0K$-806.0K$-469.0K$-4M$-739.0K$-179.0K$-1M$-1M
Pretax Income $-57M$-12M$-3M$-9M$-140.0K$-7M$-6M$-8M$-3M$-3M$-4M$4M
Income Tax $-686.0K$740.0K$859.0K$337.0K$148.0K$518.0K$-815.0K$-4M$-605.0K$1M$15M$2M
Net Income $-57M$-12M$-3M$-10M$-288.0K$-8M$-5M$-3M$-865.0K$-4M$-19M$2M
EPS (Basic) $-1.28$-0.28$-0.08$-0.23$-0.01·$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
EPS (Diluted) $-1.28$-0.28$-0.08$-0.23··$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
Shares (Basic) 44,391,00043,538,00042,420,00041,413,00040,343,00038,640,00037,813,58036,453,12634,753,32534,211,52133,592,77532,170,683
Shares (Diluted) 44,391,00043,538,00042,420,00041,413,00040,343,00038,640,00037,813,58036,453,12634,753,32534,211,52133,592,77533,236,569
EBITDA $-49M$-6M$2M$-7M$2M$221.0K$377.0K$984.0K$-101.0K$-3M$-2M·
Balance general 28
Métrica Tendencia 202520242023202220212020201920182017201620152014
Cash & Equivalents $9M$4M$4M$5M$8M$8M$8M$8M$6M$6M$7M$14M
Receivables $16M$15M$16M$17M$22M$18M$21M$21M$13M$16M$18M$16M
Inventory $21M$23M$25M$26M$28M$22M$22M$25M$17M$20M$22M$21M
Other Current Assets $3M$3M$4M$3M$4M$3M$2M$3M$4M$4M$4M$5M
Current Assets $48M$45M$49M$51M$62M$52M$54M$58M$48M$45M$51M$57M
PP&E (Net) $5M$5M$4M$3M$3M$4M$5M$6M$4M$4M$6M$5M
PP&E (Gross) $23M$21M$18M$18M$18M$21M$20M$23M$19M$19M$22M$20M
Accum. Depreciation $18M$16M$14M$15M$14M$17M$15M$17M$16M$15M$16M$15M
Goodwill $10M$56M$57M$56M$58M$59M$57M$57M$36M$38M$40M$40M
Intangibles $8M$11M$16M$21M$27M$33M$38M$46M$10M$17M$21M$21M
Other Non-current Assets $3M$3M$6M$8M$5M$1M$2M$2M$324.0K$128.0K$152.0K$380.0K
Total Assets $80M$127M$137M$145M$162M$156M$165M$169M$109M$108M$120M$136M
Accounts Payable $4M$5M$6M$6M$5M$6M$5M$7M$4M$6M$9M$6M
Accrued Liabilities ······$6M$7M$4M$5M$4M$4M
Current Liabilities $22M$55M$27M$23M$25M$21M$25M$25M$14M$15M$19M$18M
Capital Leases $7M$6M$5M$5M$6M$7M$8M·····
Deferred Tax $317.0K$710.0K$776.0K$590.0K$2M$2M$2M$2M$3M$6M$4M$1M
Other Non-current Liabilities $1M$1M$1M$1M$486.0K$3M$749.0K$3M····
Total Liabilities $66M$63M$64M$73M$79M$80M$83M$86M$28M$36M$42M$40M
Long-term Debt $36M$37M$37M$47M$48M$48M$54M$61M$12M$14M$19M$21M
Total Debt $36M$37M$37M$47M$49M$48M$50M$59M$9M$11M$16M·
Common Stock $447.0K$441.0K$434.0K$454.0K$452.0K$444.0K$438.0K$436.0K$419.0K$418.0K$416.0K$397.0K
Retained Earnings $-215M$-158M$-146M$-142M$-133M$-132M$-125M$-120M$-117M$-116M$-112M$-93M
Treasury Stock ····$0$11M······
AOCI $-12M$-16M$-14M$-15M$-10M$-13M$-13M$-14M$-11M$-17M$-12M$-8M
Stockholders' Equity $14M$63M$73M$72M$83M$77M$82M$83M$81M$72M$78M$95M
Liabilities + Equity $80M$127M$137M$145M$162M$156M$165M$169M$109M$108M$120M$136M
Shares Outstanding 4,471,98944,074,47543,394,50942,081,70741,142,87639,407,08038,188,20837,378,80235,018,47835,018,47833,979,26532,563,256
Flujo de Efectivo 16
Métrica Tendencia 202520242023202220212020201920182017201620152014
Stock-based Comp $2M$4M$5M$4M$4M$4M$3M$3M$4M$3M$3M$2M
Deferred Tax $-553.0K$310.0K$228.0K$-498.0K$-371.0K$-143.0K$-398.0K$-4M$-2M$-279.0K$15M$1M
Amort. of Intangibles $4M$5M$6M$6M$6M$6M$6M$5M$2M$3M$3M$3M
Restructuring $200.0K$800.0K$391.0K$2M$1M$2M$1M·$0$-4.0K$788.0K$1M
Operating Cash Flow $7M$1M$14M$1M$1M$9M$8M$3M$1M$5M$705.0K$4M
CapEx $1M$3M$2M$2M$1M$1M$1M$986.0K$890.0K···
Investing Cash Flow $-2M$-1M$-2M$-2M$-1M$-1M$-229.0K$-54M$-917.0K$-62.0K$-8M$-14M
Debt Issued $40M$0··········
Net Debt Issued $15M$-6M$-4M$-3M$-4M$-67M$-12M$-20M$-5M$-9M$-8M·
Stock Issued ·······$5M$160.0K$182.0K$2M$2M
Net Stock Activity ·······$5M$160.0K$182.0K$2M·
Financing Cash Flow $-1M$-131.0K$-12M$-3M$-252.0K$-8M$-8M$53M$-2M$-5M$-540.0K$-1M
Net Change in Cash $5M$-175.0K$-225.0K$-3M$-496.0K$-18.0K$162.0K$2M$137.0K$-1M$-7M$-12M
Taxes Paid $-98.0K$-159.0K$207.0K$534.0K$577.0K$416.0K$374.0K$98.0K$13.0K···
Free Cash Flow $5M$-1M$12M$-438.0K$67.0K$8M$7M$2M····
Levered FCF ·······$-995.1K····
Rentabilidad 8
Métrica Tendencia 202520242023202220212020201920182017201620152014
Gross Margin 57.7%58.2%58.9%53.7%56.9%56.9%55.4%52.3%46.7%46.3%44.8%·
Operating Margin -56.1%-6.6%1.7%-6.1%1.7%0.22%0.32%0.81%-0.10%-2.9%-1.6%·
Net Margin -65.5%-13.2%-3.0%-8.4%-0.24%-7.6%-4.0%-2.4%-0.85%-4.1%-17.5%·
Pretax Margin -66.3%-12.4%-2.3%-8.1%-0.12%-7.1%-4.7%-6.6%-2.1%-2.9%-3.3%·
EBITDA Margin -56.1%-6.6%1.7%-6.1%1.7%0.22%0.32%0.81%-0.10%-2.9%-1.6%·
ROA -54.9%-9.4%-2.4%-6.2%-0.18%-4.9%-2.8%-2.1%-0.80%-3.8%-14.9%·
ROE -384.8%-19.3%-4.6%-13.2%-0.36%-10.2%-5.9%-3.6%-1.1%-5.8%-22.0%·
ROIC -96.8%-6.6%2.3%-6.0%3.2%0.19%0.24%0.37%-0.05%-5.0%-9.6%·
Liquidez y Solvencia 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Current Ratio 2.20.81.82.22.42.52.12.73.43.12.6·
Quick Ratio 1.10.30.80.91.21.21.11.41.61.51.3·
Debt / Equity 2.60.60.50.70.60.60.60.70.10.20.2·
LT Debt / Equity 2.60.00.40.60.50.60.60.70.10.20.2·
Interest Coverage ·······0.2-0.1-4.7-2.0·
Eficiencia 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Asset Turnover 0.80.70.80.70.70.60.70.90.90.90.8·
Inventory Turnover 1.71.61.81.92.12.02.22.72.62.72.8·
Receivables Turnover 5.66.16.85.96.05.35.56.96.46.36.5·
Por Acción 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Book Value / Share $0.31$1.44$1.68$1.72$2.03$1.95$2.14$2.21$2.31$2.10$2.28·
Revenue / Share $1.95$2.16$2.65$2.74$2.95$2.64$3.07$3.31$2.93$3.06$3.23·
Cash Flow / Share $0.15$0.03$0.33$0.03$0.03$0.24$0.21$0.08$0.03$0.16$0.02·
Cash / Share $0.19$0.09$0.10$0.11$0.19$0.21$0.22$0.22$0.16$0.16$0.20·
EPS (TTM) $-1.28$-0.28$-0.08$-0.23·$-0.21$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
Tasas de Crecimiento 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue YoY -8.1%-16.1%-0.96%-4.7%16.5%·······
Revenue CAGR 3Y -8.6%-7.5%3.2%·········
Revenue CAGR 5Y -3.2%···········
Valoración (TTM) 13
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue TTM $87M$94M$112M$113M$119M$102M$116M$121M$77M$105M$109M$109M
Net Income TTM $-57M$-12M$-3M$-10M$-288.0K$-8M$-5M$-3M$-865.0K$-4M$-19M$2M
Market Cap $30M$93M$232M$117M$290M$169M$116M$119M$116M$105M$118M·
Enterprise Value $57M$126M$265M$159M$331M$209M$158M$169M$119M$111M$128M·
P/E -0.5-7.5-66.9-12.0·-20.4-25.4-39.8-165.0-23.5-6.181.0
P/S 0.31.02.11.02.41.71.01.01.51.01.1·
P/B 2.21.53.21.63.52.21.41.41.41.51.5·
P / Cash Flow 4.564.616.5101.2229.818.114.541.2109.319.5167.2·
P / FCF 5.5-77.219.0-266.14329.220.717.162.6····
EV / EBITDA -1.2-20.3139.8-23.0160.1945.8419.8172.2-1176.3-37.0-74.5·
EV / FCF 10.5-104.821.6-363.44938.025.623.289.3····
EV / Revenue 0.71.32.41.42.82.01.41.41.51.11.2·
Earnings Yield -191.0%-13.3%-1.5%-8.3%·-4.9%-3.9%-2.5%-0.61%-4.3%-16.4%1.2%

Período más reciente a la izquierda · valores nulos mostrados como ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

16
Métrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $87M $94M $112M $113M $119M
Margen Bruto % 57.7% 58.2% 58.9% 53.7% 56.9%
Margen Operativo % -56.1% -6.6% 1.7% -6.1% 1.7%
Beneficio neto $-57M $-12M $-3M $-10M $-288.0K
EPS Diluido $-1.28 $-0.28 $-0.08 $-0.23 ·

Propietarios institucionales (13F) 8 declarantes · $5.7M total · A fecha de 30 de junio de 2026

17

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Tenedores 8
Valor en tenencia $5.7M
Nuevas posiciones 0
Posiciones cerradas 0
Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
0 (0 vs trimestre anterior) 0 (-57 vs trimestre anterior) 2 (+2 vs trimestre anterior) 0 (-3 vs trimestre anterior) +90K

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
AMH Equity Ltd $1 774 844 4 047 535 31,32% Acciones
VANGUARD GROUP INC $1 286 671 1 923 275 22,71% Acciones
Meros Investment Management, LP $1 125 401 182 992 19,86% Acciones
NANO CAP NEW MILLENNIUM GROWTH FUND L P $879 954 143 082 15,53% Acciones
TWO SIGMA ADVISERS, LP $587 578 878 556 10,37% Acciones
Point72 Asia (Singapore) Pte. Ltd. $6 445 14 697 0,11% Acciones
WOLVERINE TRADING, LLC $5 102 11 600 0,09% Opción de compra
Financial Connections Group, Inc. $0 30 0,00% Acciones

Activistas y propietarios del %+ 5 5 tenencias

18

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider 23 de marzo de 2026 15,97% Presentación inicial · SEC
ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 presentaciones 22 de junio de 2020 · Presentación inicial · SEC
HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 presentaciones 20 de mayo de 2008 · Presentación inicial · SEC
14 de diciembre de 2007 · Presentación inicial · SEC
Persona informante no revelada 29 de julio de 2002 · Presentación inicial M&A / venta SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Informantes de la empresa 34 insiders · 14 directivos · 18 consejeros

19
Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
John D Duke Chief Executive Officer 20 de marzo de 2026 A 180 000 1 0 $25 050
Jeffrey Duchemin Chief Executive Officer 7 de julio de 2019 D 464 528 0 0 $0
Mark T Frost Chief Financial Officer 20 de marzo de 2026 A 47 500 1 0 $25 000
Jennifer Cote Chief Financial Officer 19 de marzo de 2025 F 159 019 0 0 $0
Michael A. Rossi Chief Financial Officer 29 de diciembre de 2022 F 260 540 0 0 $0
Kamalam Unninayar Chief Financial Officer 7 de marzo de 2019 A 73 858 0 0 $0
Bryce Anthony Chicoyne Chief Financial Officer 1 de mayo de 2007 A · 0 0 $0
Mark A Norige President, Harvard Apparatus 1 de mayo de 2007 A · 0 0 $0
David L Strack President of Subsidiary 25 de mayo de 2005 A · 0 0 $0
Kenneth Fletcher Olson Chief Operating Officer 29 de diciembre de 2021 F 155 595 0 0 $0
Yash Singh Executive Vice President 31 de octubre de 2019 A 39 286 0 0 $0
Yong Sun VP - Commercial Operations 1 de enero de 2019 F 242 805 0 0 $0
Yoav Sibony VP - Global Sales 3 de agosto de 2015 A 21 582 0 0 $0
Paul Bailey VP, Finance & Admin. 25 de mayo de 2005 A · 0 0 $0
Seth Benjamin Benson Consejero 9 de junio de 2026 A 27 556 0 0 $0
Katherine A. Eade Consejero 9 de junio de 2026 A 58 669 0 0 $0
Robert E. Gagnon Consejero 9 de junio de 2026 A 27 556 0 0 $0
William Snider Consejero 9 de junio de 2026 A 48 556 2 0 $103 604
Stephen J Denelsky Consejero 9 de junio de 2026 A 37 556 1 0 $48 700
James W Green Consejero 15 de agosto de 2025 D 2 452 566 0 0 $0
Thomas W Loewald Consejero 21 de mayo de 2024 A 295 311 0 0 $0
Bertrand Loy Consejero 21 de mayo de 2024 A 56 575 0 0 $0
Alan I Edrick Consejero 21 de mayo de 2024 A 273 911 0 0 $0
John F Kennedy Consejero 23 de marzo de 2021 G 323 344 0 0 $0
Susan M. Steele Consejero 4 de enero de 2021 A 49 400 0 0 $0
George Uveges Consejero 12 de marzo de 2018 M 142 685 0 0 $0
Earl R Lewis Consejero 2 de enero de 2018 A 477 050 0 0 $0
David Green Consejero 7 de febrero de 2017 S 925 571 0 0 $0
Neal J Harte Consejero 25 de mayo de 2016 M 106 399 0 0 $0
Robert A Dishman Consejero 28 de abril de 2015 A 51 055 0 0 $0
Chane Graziano Propietario del 10% 7 de noviembre de 2013 G 3 005 150 0 0 $0
HSO LIMITED PARTNERSHIP Propietario del 10% 16 de mayo de 2008 S 2 757 257 0 0 $0
Thomas Mcnaughton · 1 de noviembre de 2013 J 171 613 0 0 $0
Susan M Luscinski · 1 de noviembre de 2013 J 469 720 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Propiedad de ETFs Mantenido por 2 ETFs

20

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
VXF · VANGUARD INDEX FUNDS 0,00% 42 043 SH 19 de agosto de 2026 Diario
VTI · VANGUARD INDEX FUNDS 0,00% 123 470 SH 19 de agosto de 2026 Diario

HBIO Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

21
calificación · 8 analistas COMPRA
Objetivo mediano $7.50 -10,1%
2 25,0% Compra fuerte
4 50,0% Compra
2 25,0% Mantener
0 0,0% Venta
0 0,0% Venta fuerte

Precio objetivo a 12 meses

1 analistas · 2026-09-20

Objetivo medio $7.50 -10,1%

Mín$7.50 Media$7.50 Máx$7.50

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

22

Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
HBIO $30M -0.5 -8.1% -65.5% -384.8% 57.7%
HYFT · · · -89.7% -78.9% 58.8%
CIRC · · · · · ·
RPID · -2.8 19.7% -140.3% -107.4% ·
BNGO $16M -0.3 -7.4% -92.6% -58.8% ·
TMO $257.86B 32.7 3.9% 15.0% 13.0% ·

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

26

Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Fuente: SEC 10-Q presentada el Ago 11, 2026